louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05164588: A Prospective Study of Traumatic Eye Injuries in the Period From January 2022 to June 2022 in Sohag University Hospitals
Official title: A Prospective Study of Traumatic Eye Injuries in the Period From January 2022 to June 2022 in Sohag University Hospitals
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Eye Injuries
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2021-12-20
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All diagnosed cases of eye trauma, regardless of gender, laterality, duration of presentation and other chronic systemic illness

Brief summary: Ocular trauma is one of the main causes of severe ocular morbidity. It represents a serious public health problem and leading cause of visual impairment. It is an important and preventable cause of visual impairment in both developing and developed countries.


Eligibility criteria: Inclusion Criteria:

* All diagnosed cases of eye trauma, regardless of gender, laterality, duration of presentation and other chronic systemic illness

Exclusion Criteria:

* patients with previous history of eye trauma or other pathological condition affecting visual acuity

Primary outcomes:
measure: Evaluate eye trauma cases at Sohag University Hospitals through statistical methods
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University Hospital
Study officials:
References:
citation: Mir TA, Canner JK, Zafar S, Srikumaran D, Friedman DS, Woreta FA. Characteristics of Open Globe Injuries in the United States From 2006 to 2014. JAMA Ophthalmol. 2020 Mar 1;138(3):268-275. doi: 10.1001/jamaophthalmol.2019.5823.
citation: Matsa E, Shi J, Wheeler KK, McCarthy T, McGregor ML, Leonard JC. Trends in US Emergency Department Visits for Pediatric Acute Ocular Injury. JAMA Ophthalmol. 2018 Aug 1;136(8):895-903. doi: 10.1001/jamaophthalmol.2018.2062.
citation: Low L, Hodson J, Morris D, Desai P, MacEwen C. Socioeconomic deprivation and serious ocular trauma in Scotland: a national prospective study. Br J Ophthalmol. 2017 Oct;101(10):1395-1398. doi: 10.1136/bjophthalmol-2016-309875. Epub 2017 Mar 8.
Clinical trial NCT01264588: The Effects of Topical Calcium Glycerophosphate on Surgical Wound Healing and Residual Scarring
Official title: A Randomized, Single Blind, Comparative, Controlled Study On The Effects Of Topical Calcium Glycerophosphate On Surgical Wound Healing And Residual Scarring In Bilateral Total Knee Arthroplasty Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Wound Healing
Scarring
Lead sponsor: AkPharma Inc.
Sponsor class: INDUSTRY
Collaborators: name: Rothman Institute Orthopaedics
name: Texas Tech University Health Sciences Center
name: Cyberderm Inc.
name: Bacharach Institute for Rehabilitation, Pomona, NJ
First posted: 2010-12-22
Enrollment: 20
Sex: ALL
Minimum age (years): 45
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine whether topical application of calcium glycerophosphate will result in superior wound appearance and scar minimization.


Eligibility criteria: Inclusion Criteria:

* Informed consent must be obtained
* 45-75 years of age
* Scheduled for bilateral knee replacement surgery

Exclusion Criteria:

* Employee or immediate family of either AkPharma or employee or immediate family of investigator or site personnel
* Pregnant or breast feeding Known allergy or hypersensitivity to calcium or phosphorus supplements
* Diagnosed with type I or type II diabetes mellitus

Primary outcomes:
measure: Improvement of surgical wound appearance
timeFrame: Post-Op Day: 3 (baseline), 7, 14, 42, 70, 98, 180, 365
Secondary outcomes:
measure: Reduction of visible erythema/ inflammation
timeFrame: Post-Op Day: 3 (baseline), 7, 14, 42, 70, 98, 180, 365
measure: Scar minimization or prevention
timeFrame: Post-Op Day: 3 (baseline), 7, 14, 42, 70, 98, 180, 365
measure: Incision/ scar pain and sensitivity
timeFrame: Post-Op Day: 3 (baseline), 7, 14, 42, 70, 98, 180, 365
measure: Range of motion
timeFrame: Post-Op Day: 3 (baseline), 7, 42, 180, 365
Other outcomes:
Locations:
city: Egg Harbor Township
country: United States
facility: Rothman Institute Orthopaedics
state: New Jersey
Study officials:
affiliation: Rothman Institute Orthopaedics
name: Alvin C. Ong, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05718388: Contralateral Isokinetic Training on Strength and Reaching Skill
Official title: Effect of Contralateral Isokinetic Training on Strength and Reaching Skill in Children With Spastic Hemiplegic Cerebral Palsy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hemiplegic Cerebral Palsy
Lead sponsor: Delta University for Science and Technology
Sponsor class: OTHER
First posted: 2023-02-08
Enrollment: 40
Sex: ALL
Minimum age (years): 5
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study aimed to ascertain how cross-education affected the activity of the paretic muscles in the upper limb and how that affected function in children with spastic hemiplegia and cerebral palsy. Additionally, it sought to determine how unilateral isokinetic resistance training affected children with spastic hemiplegia of the contralateral limb in terms of strength development.


Eligibility criteria: Inclusion Criteria:

* hemiplegic CP children from both genders with age ranged from five to seven year
* had mild to moderate spasticity according to the Modified Ashworth Scale
* able to follow verbal instructions
* able to stand unassisted and ambulate with abnormal pattern

Exclusion Criteria:

* children who had any visual or auditory problems, fixed deformities in upper limb that interfere with fine motor functions, with history of any surgical interference in upper limbs for less than one year, and un-cooperative children were excluded.

Primary outcomes:
measure: Concentric isokinetic shoulder abductors peak torque in Newton- meters and average power.
timeFrame: Change from Baseline Isokinetic dynamometer parameters at 2 months
Secondary outcomes:
measure: Modified functional scale for reaching
timeFrame: Change from Baseline Modified functional scale for reaching at 2 months
Other outcomes:
Locations:
city: Gamasa
country: Egypt
facility: Amira Hussin Mohammed
Study officials:
References:
Clinical trial NCT02312388: Comparison of the Central Venous Catheter Insertion Techniques
Official title: Comparison of the Central Venous Catheter Insertion Techniques: the Thin-wall Needle Versus the Catheter-over-the-needle Technique in Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Child
Surgery
Keywords: central venous catheters
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2014-12-09
Enrollment: 138
Sex: ALL
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to compare the differences in central venous catheter insertion time, success rate, and complication between thin-wall needle technique and catheter-over-the-needle technique for central venous catheterization in children.

Detailed description: Catheterization was performed using ultrasound with an "out-of-plane" approach by inserting the introducer needle (thin-wall needle technique) or Angiocath Plus™ catheter (catheter-over-the-needle technique) in 45 - 60° to the patient's skin while viewing the vein in a cross section.

Eligibility criteria: Inclusion Criteria:

* surgery under general anesthesia
* require central venous catheterization

Exclusion Criteria:

* hematoma in central vein
* central vein anomaly
* catheterization site infection

Primary outcomes:
measure: Guide-wire insertion time
timeFrame: interval between skin penetration and removal of the needle or catheter after guide wire insertion, an expected average of 80 seconds
Secondary outcomes:
measure: Time to first puncture of central vein
timeFrame: interval between skin penetration of the needle or catheter and flashback of blood, an expected average of 25 seconds
measure: Total time of central venous catheter insertion
timeFrame: interval between skin penetration of the needle or catheter and installation of the indwelling catheter, an expected average of 3 minutes
measure: Number of central vein puncture trial
timeFrame: up to 5 times, an expected average observation time of 25 seconds
measure: Number of guide-wire insertion trial
timeFrame: up to 5 times, an expected average observation time of 80 seconds
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Jin-Tae Kim, MD. PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04205188: The Effects of Therapeutic Exercises on Kinesiophobia in Haemophilic Patients.
Official title: Do Therapeutic Exercises Improve Kinesiophobia and Health-Related Quality of Life in Adult Haemophilia Patients? A Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Haemophilia
Lead sponsor: Cukurova University
Sponsor class: OTHER
First posted: 2019-12-19
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: this study evaluates the effects of therapeutic exercises on kinesiophobia and health-related quality of life in adult haemophilia patients. half of participants will receive therapeutic exercises and verbal information about the positive effects of therapeutic exercises on physical pathologies due to hemophilic arthropathy while the other half will receive only verbal information.

Detailed description: in haemophilia patients recurrent musculoskeletal hemorrhage cause to arthropathy characterized by severe degeneration of joint cartilage and bones. arthropathy leads to decrease in the patient's health related quality of life. furthermore pain, risk of injury and lack of motivation lead to decreased physical activity and development of kinesiophobia.

Eligibility criteria: Inclusion Criteria:

* Individuals older than 18 years
* diagnosed with hemophilia A or B
* having at least one joint with hemophilic arthropathy
* without cognitive problems
* speaking turkish

Exclusion Criteria:

* Individuals with another congenital coagulopathy such as Von Willebrand Syndrome,
* unable to walk due to hemophilic arthropathy
* developing inhibition against factor VIII-IX

Primary outcomes:
measure: tampa kinesiophobia scale
timeFrame: baseline, 8 weeks: change from baseline kinesiophobia at 8 weeks, 6 months: change from baseline kinesiophobia at 6 months
measure: haemophilia adult health-related quality of life scale
timeFrame: baseline, 8 weeks: change from baseline health-related quality of life at 8 weeks, 6 months: change from baseline health-related quality of life at 6 months
Secondary outcomes:
measure: short form-36
timeFrame: baseline, 8 weeks: change from baseline health-related quality of life at 8 weeks, 6 months: change from baseline health-related quality of life at 6 months
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Volkan Deniz
Study officials:
affiliation: Cukurova University
name: Volkan Deniz
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05529888: Measure the Serum Level of Homocysteine in Acne Patients Before and After Oral Isotretinoin.
Official title: Serum Homocysteine Level in Acne Patients Before and After Oral Isotretinoin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Acne Vulgaris
Lead sponsor: Aswan University
Sponsor class: OTHER
First posted: 2022-09-07
Enrollment: 60
Sex: ALL
Minimum age (years): 15
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: group of patients and group of control
Primary purpose: DIAGNOSTIC

Brief summary: Serum homocysteine level in Acne patients before and after oral Isotretinoin and Correlation between serum level of homocysteine in acne patients before and after Oral isotretinoin treatment

Detailed description: Acne vulgaris is a common chronic inflammatory disease of the skin. It is found in about 80% of young adults and adolescents. It is a disease that affects the pilosebaceous units of the skin and may result in inflammatory or non-inflammatory lesions,Oral isotretinoin (13-cis-retinoic acid) is the only drug that counteracts all the pathogenetic mechanisms that contribute to the development of acne The standard dose of isotretinoin is 0.5 to 1 mg/kg per day for 4 months to a cumulative dose of 120-140 mg/kg is effective in the management of acne vulgaris The scope of our study is to detect serum homocysteine level in acne patient befor and after oral isotrtinoin treatment

Eligibility criteria: Inclusion Criteria:

* Patients of both sexes with acne vulgaris

Exclusion Criteria:

* Patients with history of malignancies.
* Patients with renal and hepatic dysfunction.
* Cardiac patient.
* Pregnant, lactating and female welling to have pregnancy in the period of study.
* Patient with absorption disorder.
* Patient with history of favism.
* Patient has already been treated with isotretinoin.

Primary outcomes:
measure: Evaluation of the effect of oral isotretinoin on Serum homocysteine in acne vulgaris patients
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Aswan
country: Egypt
facility: Aswan University-Faculty of Medicine
state: New Aswan City
Study officials:
References:
Clinical trial NCT06825988: The Use of the GRASP System for Postoperative Monitoring
Official title: The Use of the GRASP System for Postoperative Monitoring - a Feasibility Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Knee Arthroplasty, Total
Rehabilitation
Keywords: digital health
tangible interaction
postoperative monitoring
rehabilitation
knee arthroplasty
mixed methods
feasibility
Lead sponsor: Haukeland University Hospital
Sponsor class: OTHER
Collaborators: name: University of Bergen
name: Grasp AS
First posted: 2025-02-13
Enrollment: 36
Sex: ALL
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The aim of this study is to explore feasibility and user experience of a novel digital system containing a handheld electronic device and a mobile application - called Grasp - in the setting of postoperative monitoring of pain and patient reported outcome measures in knee arthroplasty patients.

The investigators will use a mixed-methods approach to gain in-depth insights into feasibility and user experience of this system in order to evaluate further improvement needs of both study design and intervention before a final randomised effect study. Feasibility will be evalutated through recruittment rates, adhererance to intervention protocol and study data sampling, and completion rates. Fidelity will be assessed as number of patients who are able to do as instructed in the protocol. In addition, the investigators will explore user experience through questionnaires after 2 and 6 weeks of use and through semi-structered interviews of participants and associated physiotherapists. Interviews will be transcribed for qualitative analyses.


Eligibility criteria: Inclusion Criteria:

* Elective joint arthroplasty
* Age: 30-70 years
* Must own and be able to use a smart phone
* Speak and understand Norwegian

Exclusion Criteria:

* Not able to give informed consent

Primary outcomes:
measure: Feasibility of the intervention study
timeFrame: From enrollment to 6 weeks after surgery
measure: User experience
timeFrame: From enrollment to 6 weeks post surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Bergen
country: Norway
facility: Helse Bergen
Study officials:
References:
Clinical trial NCT03754088: In Vitro Model of the Cystic Fibrosis Bronchial Epithelium Via iPS Technology
Official title: Initiation of an in Vitro Model of the Cystic Fibrosis Bronchial Epithelium Via Induced Pluripotent Stem Cell Technology
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cystic Fibrosis
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2018-11-27
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Three cystic fibrosis patients who are homozygous for the p.Phe508del mutation and 3 healthy subjects without cystic fibrosis.

Brief summary: In order to further enable physiopathology studies, the aim of this project is to validate an in vitro model of cystic fibrosis created using induced pluripotent stemcell (iPS) differentiated bronchial epithelium from cystic fibrosis (CF) patients homozygous for the p.Phe508del mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Detailed description: The investigator's primary objective is to generate iPS lines from 3 CF patients and from 3 healthy subjects.

Secondary objectives include verification that cell lines express the CFTR gene according to their genotype, verification or relative production of the CFTR protein for each iPS line, and amplification of obtain iPS lines for aliquot creation to facilitate sharing.

Eligibility criteria: Inclusion Criteria for subjects with Cystic Fibrosis:

* Homozygote for the p.Phe508del mutation
* Signed informed consent given by the subject

Inclusion Criteria for subjects without Cystic Fibrosis:

* Signed informed consent given by the subject

Exclusion Criteria:

* Pregnancy, breastfeeding
* Participant in an exclusion period determined by a previous study
* Participant under any kind of guardianship
* Unaffiliated with or not a beneficiary of a social security program (health insurance)
* Subject deprived of liberty (e.g. prisoners)
* Subject with positive infectious markers for HIV1, HIV2, HBC or HBV

Exclusion Criteria for subjects with Cystic Fibrosis:

* Any pathology requiring a treatment or a pathology not requiring treatment but with clinical significance according to the investigator

Primary outcomes:
measure: Obtention of induced pluripotent stem cell line (iPS): yes/no
timeFrame: 28 days
Secondary outcomes:
measure: Functional bronchial epithelium present for the iPS? yes/no
timeFrame: 28 days
measure: Cystic fibrosis transmembrane conductance regulator (CFTR) channel function: yes/no
timeFrame: 28 days
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Hôpital Arnaud de Villeneuve - CHU de Montpellier
Study officials:
affiliation: Montpellier University Hospitals
name: Arnaud Bourdin, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01635478: A Observational Study of Assessment and Treatment Adequacy of Emergency Cancer Pain in Tertiary Cancer Hospital
Official title: A Prospective Observational Study of Assessment of Emergency Cancer Pain and Its Treatment Adequacy in Emergency Department of Tertiary Care Cancer Hospital.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: TO STUDY EMERGENCY CANCER PAIN PATTERNS AND TREATMENT ADEQUACY.
Lead sponsor: Tata Memorial Hospital
Sponsor class: OTHER_GOV
First posted: 2012-07-09
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: ADULT CANCER PATIENTS REPORTING TO EMERGENCY ROOM WITH COMPLAINTS PRIMARILY OF PAIN.

Brief summary: EMERGENCY CANCER PAIN MANAGEMENT HAS BEEN INCONSISTENT AND INADEQUATE ACROSS THE GLOBE. THIS STUDY AIMS TO KNOW EMERGENCY ROOM CANCER PAIN PATTERNS AND TREATMENT ADEQUACY IN TERTIARY CARE CANCER HOSPITALS.


Eligibility criteria: Inclusion Criteria:

* ADULT CANCER PATIENTS REPORTING TO EMERGENCY ROOM WITH COMPLAINTS PRIMARILY OF PAIN

Exclusion Criteria:

* PATIENTS BELOW 18 YEARS OF AGE AND PATIENTS WITH INCOHERENT BEHAVIOUR.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02455778: Effect of Oral Cinnamon Intervention in Metabolic Syndrome
Official title: Effect of Intervention With Oral Cinnamon on Metabolic Profile and Body Composition of Asian Indians With Metabolic Syndrome in North India: A 16 Week Double Blind Placebo Control Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Metabolic Syndrome
Lead sponsor: Diabetes Foundation, India
Sponsor class: OTHER
Collaborators: name: Institute of Home Economics, India
First posted: 2015-05-28
Enrollment: 103
Sex: ALL
Minimum age (years): 25
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This double blind placebo control study with supplementation of oral Cinnamon is being conducted to test the hypothesis that in subjects with Metabolic Syndrome oral cinnamon may lead to improvement in body composition and metabolic parameters.


Eligibility criteria: Inclusion Criteria:

1. Subjects aged between 25 -65 years
2. Subjects identified with any three of following:

   1. Fasting blood glucose ≥100 mg/ dL
   2. Waist circumference ≥ 90 cm ( males) ≥ 80 cm (females)
   3. Triglycerides ≥ 150 mg/dL
   4. High density lipoprotein cholesterol ≤ 40 mg/dL ( in males) , ≤ 50 mg/dL (in females)
   5. Blood pressure Systolic BP ≥ 130 mm Hg
   6. Diastolic BP ≥ 85 mm Hg
3. Subjects who were willing to participate in the study.
4. Subjects, if on medication for high blood pressure were stable and there was no change in the dosage for the past 3 months.

Exclusion Criteria:

1. Subjects suffering from other chronic diseases and metabolic complications such as cardiovascular disease, diabetes, renal disease, myocardial infarction and other endocrine disorders.
2. Subjects who were allergic to wheat flour and cinnamon.
3. Subjects who were on medication of anti dyslipidemic or hypoglycemic drugs.
4. Subjects who had undergone bypass procedure.
5. Subjects suffering from any debilitating disease such as tuberculosis, HIV etc.
6. Subjects suffering from uncontrolled hypothyroidism/ hyperthyroidism
7. Pregnant and lactating mothers

Primary outcomes:
measure: Fasting Blood Glucose
timeFrame: baseline to 4 months
Secondary outcomes:
measure: HbA1c
timeFrame: baseline to 4 months
measure: Lipid profile
timeFrame: baseline to 4 months
measure: Body fat percentage
timeFrame: baseline to 4 months
measure: Blood pressure
timeFrame: baseline to 4 months
Other outcomes:
Locations:
city: Delhi
country: India
facility: Fortis-C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology
Study officials:
References:
citation: Gupta Jain S, Puri S, Misra A, Gulati S, Mani K. Effect of oral cinnamon intervention on metabolic profile and body composition of Asian Indians with metabolic syndrome: a randomized double -blind control trial. Lipids Health Dis. 2017 Jun 12;16(1):113. doi: 10.1186/s12944-017-0504-8.